Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 6;7(2):781.
doi: 10.4102/ajlm.v7i2.781. eCollection 2018.

Drug resistant tuberculosis in Africa: Current status, gaps and opportunities

Affiliations

Drug resistant tuberculosis in Africa: Current status, gaps and opportunities

Nazir Ismail et al. Afr J Lab Med. .

Abstract

Background: The World Health Organization End TB Strategy targets for 2035 are ambitious and drug resistant tuberculosis is an important barrier, particularly in Africa, home to over a billion people.

Objective: We sought to review the current status of drug resistant tuberculosis in Africa and highlight key areas requiring improvement.

Methods: Available data from 2016 World Health Organization global tuberculosis database were extracted and analysed using descriptive statistics.

Results: The true burden of drug resistant tuberculosis on the continent is poorly described with only 51% of countries having a formal survey completed. In the absence of this data, modelled estimates were used and reported 92 629 drug resistant tuberculosis cases with 42% of these occurring in just two countries: Nigeria and South Africa. Of the cases estimated, the majority of patients (70%) were not notified, representing 'missed cases'. Mortality among patients with multi-drug resistant tuberculosis was 21%, and was 43% among those with extensively drug resistant tuberculosis. Policies on the adoption of new diagnostic tools was poor and implementation was lacking. A rifampicin result was available for less than 10% of tuberculosis cases in 23 of 47 countries. Second-line drug resistance testing was available in only 60% of countries. The introduction of the short multi-drug resistant tuberculosis regimen was a welcome development, with 40% of countries having implemented it in 2016. Bedaquiline has also been introduced in several countries.

Conclusion: Drug resistant tuberculosis is largely missed in Africa and this threatens prospects to achieve the 2035 targets. Urgent efforts are required to confirm the true burden of drug resistant tuberculosis in Africa. Adoption of new tools and drugs is essential if the 2035 targets are to be met.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.

Figures

FIGURE 1
FIGURE 1
Multi-drug-resistant tuberculosis outcomes by country grouped by size of cohort: 2014. Countries with no data or no reported cases are not shown.

Similar articles

Cited by

References

    1. WHO Global TB report. 2016. [cited 2018 January 22]. Available from: http://www.who.int/tb/publications/global_report/gtbr2016_executive_summ...
    1. WHO WHO END TB strategy. 2015. [cited 2018 January 22]. Available from: http://www.who.int/tb/End_TB_brochure.pdf?ua=1
    1. WHO Global TB report. 2017. [cited 2018 August 27]. Available from: http://www.who.int/tb/publications/global_report/gtbr2016_executive_summ...
    1. Abdool Karim SS, Churchyard GJ, Karim QA, Lawn SD. HIV infection and tuberculosis in South Africa: An urgent need to escalate the public health response. Lancet. 2009;374(9693):921–933. https://doi.org/10.1016/S0140-6736(09)60916-8 - DOI - PMC - PubMed
    1. Harries AD, Hargreaves NJ, Kemp J, et al. . Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet. 2001;357(9267):1519–1523. https://doi.org/10.1016/S0140-6736(00)04639-0 - DOI - PubMed

LinkOut - more resources